GlassScriptPhysician profile
Bimal T Patel
NPI 1841298221
$8,316.16
in general payments reported to CMS, 2019-2025
56 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $237 · 2021: $1,506 · 2022: $2,195 · 2023: $1,039 · 2024: $1,183 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.44 |
| Education | $268.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,139.50 | 2021-2024 | Enhertu |
| Novartis Pharmaceuticals Corporation | $527.78 | 2019-2025 | |
| Janssen Biotech, INC. | $467.71 | 2019-2025 | Darzalex, Rybrevant, Erleada |
| Pfizer INC. | $355.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $343.60 | 2021-2025 | Ninlaro, Iclusig |
| Foundation Medicine, INC. | $300.00 | 2019 | |
| US Oncology Corporate, INC. | $248.79 | 2024 | |
| Glaxosmithkline, LLC. | $239.00 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Celgene Corporation | $232.94 | 2021-2025 | Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $230.95 | 2019-2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $220.16 | 2020-2025 | |
| Astellas Pharma US INC | $218.04 | 2019-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $216.12 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Array Biopharma INC | $209.19 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $158.24 | 2020-2023 | Epkinly |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $149.61 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $145.89 | 2020-2025 | Jakafi, Monjuvi |
| Kite Pharma, INC. | $140.83 | 2021-2022 | |
| Abbvie INC. | $137.84 | 2024-2025 | |
| Genzyme Corporation | $114.68 | 2021-2023 | |
| Gilead Sciences, INC. | $101.71 | 2023-2025 | Trodelvy |
| Genentech USA, INC. | $101.31 | 2019-2025 | Polivy, Venclexta |
| Lilly USA, LLC | $97.92 | 2019-2025 | Verzenio, Jaypirca |
| Eisai INC. | $97.46 | 2021-2024 | |
| Seagen INC. | $96.66 | 2019-2023 | Adcetris |
| Dendreon Pharmaceuticals LLC | $82.67 | 2022 | |
| Tersera Therapeutics LLC | $67.14 | 2024-2025 | Zoladex |
| Springworks Therapeutics, INC. | $64.71 | 2025 | Ogsiveo, Gomekli |
| Acrotech Biopharma INC. | $61.63 | 2021-2023 | Beleodaq |
| Beone Medicines USA, INC. | $55.18 | 2025 | Tevimbra |
| Adc Therapeutics America, INC. | $49.71 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.10 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.92 | 2021-2022 | |
| Intuitive Surgical, INC. | $41.67 | 2019 | |
| Deciphera Pharmaceuticals INC. | $34.83 | 2025 | Romvimza, Qinlock |
| Mirati Therapeutics, INC. | $34.31 | 2023-2024 | Krazati |
| Amgen INC. | $30.59 | 2019-2023 | Kyprolis, Blincyto |
| Octapharma USA, INC. | $30.00 | 2023 | Octagam Immune Globulin (Human) |
| Blueprint Medicines Corporation | $28.27 | 2023 | Ayvakit |
| Beigene USA, INC. | $24.44 | 2024 | Brukinsa |
| Global Blood Therapeutics, INC. | $24.32 | 2022 | |
| Cti Biopharma Corp. | $23.88 | 2022 | |
| Rigel Pharmaceuticals, INC. | $23.56 | 2019 | |
| Morphosys, US INC. | $22.81 | 2022 | |
| Redhill Biopharma INC. | $22.12 | 2021 | |
| Heron Therapeutics, INC. | $21.66 | 2020 | |
| Myriad Genetic Laboratories, INC. | $21.26 | 2024 | Myrisk |
| Servier Pharmaceuticals LLC | $20.91 | 2024 | |
| Tesaro, INC. | $20.22 | 2019 | |
| Cardinal Health 414 LLC | $20.14 | 2024 | Kit For The Preparation of Lymphoseek (Technetium Tc 99m Tilmanocept) |
| Genmab U.S., INC. | $20.04 | 2024 | Epkinly |
| Janssen Pharmaceuticals, INC | $19.44 | 2021 | |
| Taiho Oncology, INC. | $18.37 | 2025 | |
| Fennec Pharmaceuticals, INC. | $17.18 | 2025 | Fyarro |
| Accord Healthcare, INC. | $16.66 | 2025 | |
| Advanced Accelerator Applications | $15.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bimal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.